- Home
- CLPR vs QNCX Comparison
CLPR vs QNCX Comparison
Compare CLPR & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- QNCX
- Stock Information
- Founded
- CLPR 2015
- QNCX 2012
- Country
- CLPR United States
- QNCX United States
- Employees
- CLPR N/A
- QNCX N/A
- Industry
- CLPR Real Estate Investment Trusts
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLPR Real Estate
- QNCX Health Care
- Exchange
- CLPR Nasdaq
- QNCX Nasdaq
- Market Cap
- CLPR 57.8M
- QNCX 47.7M
- IPO Year
- CLPR 2017
- QNCX 2019
- Fundamental
- Price
- CLPR $3.90
- QNCX $1.31
- Analyst Decision
- CLPR
- QNCX Strong Buy
- Analyst Count
- CLPR 0
- QNCX 5
- Target Price
- CLPR N/A
- QNCX $8.00
- AVG Volume (30 Days)
- CLPR 76.2K
- QNCX 302.6K
- Earning Date
- CLPR 07-31-2025
- QNCX 08-12-2025
- Dividend Yield
- CLPR 9.91%
- QNCX N/A
- EPS Growth
- CLPR N/A
- QNCX N/A
- EPS
- CLPR N/A
- QNCX N/A
- Revenue
- CLPR $152,413,000.00
- QNCX N/A
- Revenue This Year
- CLPR N/A
- QNCX N/A
- Revenue Next Year
- CLPR N/A
- QNCX N/A
- P/E Ratio
- CLPR N/A
- QNCX N/A
- Revenue Growth
- CLPR 8.63
- QNCX N/A
- 52 Week Low
- CLPR $3.38
- QNCX $0.51
- 52 Week High
- CLPR $7.12
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- CLPR 49.60
- QNCX 64.64
- Support Level
- CLPR $3.80
- QNCX $1.29
- Resistance Level
- CLPR $4.06
- QNCX $1.45
- Average True Range (ATR)
- CLPR 0.15
- QNCX 0.09
- MACD
- CLPR -0.01
- QNCX 0.03
- Stochastic Oscillator
- CLPR 29.17
- QNCX 76.74
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.